Management of Syncope in a Pregnant Woman at 27 Weeks Gestation
For a 22-year-old pregnant woman at 27 weeks gestation with a history of syncopal episodes, beta-blocker therapy is the next best treatment after initial evaluation to identify the underlying cause.
Initial Evaluation
Before initiating treatment, a targeted evaluation should be performed to identify the underlying cause of syncope:
- Laboratory testing: Complete blood count, electrolytes, glucose, and thyroid function tests 1
- Cardiovascular assessment: 12-lead ECG to assess for arrhythmias 1
- Red flags requiring immediate attention:
- Focal neurological deficits
- New-onset severe headache
- Atypical or persistent vertigo
- Abnormal neurological examination
- Signs of pre-eclampsia
- Significant cardiac symptoms 1
Treatment Algorithm
First-line treatment: Beta-blockers
Alternative treatments if beta-blockers are contraindicated:
For specific arrhythmia-related causes:
Special Considerations
- Avoid amiodarone due to its fetotoxic effects unless other agents fail 2
- Electrical cardioversion should be considered if the patient becomes hemodynamically unstable due to arrhythmia 2
- Anticoagulation may be necessary if arrhythmia is detected, with heparin preferred over warfarin during pregnancy 2
Patient Education and Safety
- Advise patient to:
- Avoid activities with risk of falling
- Avoid excessive heat exposure
- Stop physical activity and seek medical attention if dizziness persists 1
- Maintain adequate hydration and avoid prolonged standing
Follow-up Recommendations
- Moderate symptoms: Follow-up within 1-2 weeks
- Severe symptoms: Immediate specialist referral 1
- Monitor fetal well-being regularly as syncope can potentially impact uteroplacental perfusion 3
Potential Complications
Syncope during pregnancy carries risks for both mother and fetus, including:
- Risk of injury from falls
- Uteroplacental insufficiency
- Psychological effects
- Interruptions in prenatal care 3
Beta-blockers represent the safest and most effective first-line treatment for recurrent syncope in pregnancy, with established efficacy in preventing syncopal episodes while maintaining maternal and fetal safety.